Insulet (PODD) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Insulet (NASDAQ: PODD):

• 8/9/2026 – Insulet was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 8/6/2026 – Insulet was given a new $175.00 price target by Robert W. Baird.
• 8/6/2026 – Insulet had its price target lowered by Sanford C. Bernstein from $200.00 to $175.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Insulet had its price target lowered by Royal Bank Of Canada from $245.00 to $160.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Insulet was downgraded by BTIG Research from “buy” to “neutral”.
• 8/6/2026 – Insulet had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $180.00 price target on the stock.
• 8/6/2026 – Insulet had its price target lowered by Canaccord Genuity Group Inc. from $249.00 to $179.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Insulet had its price target lowered by TD Cowen from $294.00 to $144.00. They now have a “hold” rating on the stock.
• 8/6/2026 – Insulet had its price target lowered by UBS Group AG from $174.00 to $150.00. They now have a “neutral” rating on the stock.
• 8/6/2026 – Insulet had its price target lowered by Benchmark Co. from $250.00 to $185.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Insulet had its price target lowered by Stifel Nicolaus from $225.00 to $180.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Insulet was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $145.00 price target on the stock, down from $247.00.
• 8/6/2026 – Insulet had its “neutral” rating reaffirmed by JPMorgan Chase & Co.. They now have a $152.00 price target on the stock, down from $275.00.
• 8/5/2026 – Insulet was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $144.00 price target on the stock, down from $255.00.
• 8/5/2026 – Insulet had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $153.00 price target on the stock, down from $210.00.
• 8/5/2026 – Insulet was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 8/1/2026 – Insulet was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/28/2026 – Insulet was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $174.00 price target on the stock.
• 7/28/2026 – Insulet is now covered by UBS Group AG. They set a “neutral” rating and a $174.00 price target on the stock.
• 7/13/2026 – Insulet had its price target lowered by Truist Financial Corporation from $219.00 to $210.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Insulet had its price target lowered by Royal Bank Of Canada from $280.00 to $245.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Insulet had its price target lowered by Stifel Nicolaus from $250.00 to $225.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Insulet had its price target raised by Citigroup Inc. from $165.00 to $172.00. They now have a “neutral” rating on the stock.
• 7/6/2026 – Insulet was given a new $180.00 price target by Evercore Inc.
• 6/27/2026 – Insulet was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/24/2026 – Insulet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/23/2026 – Insulet is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $190.00 price target on the stock.

Insider Activity

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.